Investor Dashboard

News Releases

Date Title and Summary Additional Formats
Toggle Summary Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist
Acelarin plus Cisplatin’s High Objective Response Rate and Favorable Safety Profile Confirmed NuTide:121 Global Phase III Study Recruitment Ongoing EDINBURGH, United Kingdom , Nov. 30, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the final results of the Phase Ib study of
View HTML
Toggle Summary NuCana Reports Third Quarter 2020 Financial Results and Provides Business Update
Completed Successful $ 8 0   million Public Offering Presented Encouraging Data for NUC-3373 and NUC-7738 at the ESMO Virtual Congress 2020 EDINBURGH, United Kingdom , Nov. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30,
View HTML
Toggle Summary NuCana to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
EDINBURGH, United Kingdom , Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Piper Sandler 32nd Annual Healthcare Conference being held
View HTML
Toggle Summary NuCana to Present at the Jefferies Virtual London Healthcare Conference
EDINBURGH, United Kingdom , Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual London Healthcare Conference .
View HTML
Toggle Summary NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar
Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering EDINBURGH, United Kingdom , Oct. 13, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the
View HTML
Toggle Summary NuCana Presents Three Posters at the ESMO Virtual Congress 2020
Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302) NUC-3373’s Favorable Pharmacokinetic and Safety Profile Unaffected by Leucovorin First-in-Human Data of NUC-7738 Shows Anti-Cancer Activity and a
View HTML
Toggle Summary NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
EDINBURGH, United Kingdom , Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the closing of its previously announced underwritten public offering of 17,888,889
View HTML
Toggle Summary NuCana Announces Pricing of a Public Offering of American Depositary Shares
EDINBURGH, United Kingdom , Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the pricing of an underwritten public offering of 15,555,556 American Depositary Shares
View HTML
Toggle Summary NuCana Announces Proposed Public Offering of American Depositary Shares
EDINBURGH, United Kingdom , Sept. 16, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that it has commenced an underwritten public offering of its American Depositary
View HTML
Toggle Summary NuCana Reports Second Quarter 2020 Financial Results and Provides Business Update
EDINBURGH, United Kingdom , Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
View HTML